<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839007</url>
  </required_header>
  <id_info>
    <org_study_id>NIL-CDNP-CT005</org_study_id>
    <nct_id>NCT00839007</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure</brief_title>
  <official_title>A Multi-Center, Single-Blind, Placebo-Controlled Phase 2 Study Assessing the Safety and Efficacy of Intravenous CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nile Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nile Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety and tolerability of IV&#xD;
      administration of CD-NP and the dose relationship of CD-NP on improvement of clinical&#xD;
      symptoms and renal function in ADHF patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurence of hypotensive events, clinical symptoms, and renal function change with CD-NP infusion.</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 of CD-NP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 of CD-NP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 of CD-NP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 of CD-NP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 5 of CD-NP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 6 of CD-NP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD-NP</intervention_name>
    <description>Infusion of CD-NP at one of up to 6 doses or placebo</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
    <arm_group_label>G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Hospitalized for acute decompensated heart failure.&#xD;
&#xD;
          2. Systolic blood pressure ≥ 115 mmHg and ≤ 200 mmHg, and diastolic blood pressure ≥ 60&#xD;
             mmHg and ≤ 110 mmHg at screening&#xD;
&#xD;
          3. Renally compromised.&#xD;
&#xD;
          4. Female patients must be post-menopausal or surgically sterile.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Acute or suspected acute myocardial infarction (AMI) or troponin levels &gt; 3X the upper&#xD;
             limit of normal at the institution's local laboratory&#xD;
&#xD;
          2. Cardiogenic shock&#xD;
&#xD;
          3. Evidence of uncorrected volume or sodium depletion other clinical condition that would&#xD;
             predispose the patient to adverse events&#xD;
&#xD;
          4. Clinically significant aortic or mitral valve stenosis&#xD;
&#xD;
          5. Temperature &gt;38°C (oral or equivalent), sepsis or active infection requiring IV&#xD;
             anti-microbial treatment&#xD;
&#xD;
          6. ADHF due to significant arrhythmias&#xD;
&#xD;
          7. Severe renal failure defined as creatinine clearance &lt; 30 mL/min&#xD;
&#xD;
          8. Current or planned ultrafiltration, hemofiltration, or dialysis&#xD;
&#xD;
          9. Significant pulmonary disease&#xD;
&#xD;
         10. Major neurologic event, including cerebrovascular events in the prior 60 days.&#xD;
&#xD;
         11. Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive&#xD;
             cardiomyopathy (not including restrictive mitral filling patterns)&#xD;
&#xD;
         12. Known hypersensitivity or allergy to natriuretic peptide or its components,&#xD;
             nesiritide, other natriuretic peptides or related compounds&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsiao Lieu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nile Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuerzberg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nazareth</city>
        <zip>16100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nilethera.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <last_update_submitted>September 15, 2010</last_update_submitted>
  <last_update_submitted_qc>September 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hsiao Lieu, MD, Vice President, Clinical Research</name_title>
    <organization>Nile Therapeutics, Inc.</organization>
  </responsible_party>
  <keyword>ADHF</keyword>
  <keyword>AHF</keyword>
  <keyword>HF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

